A federal jury has found in favor of RyMed Technologies and against ICU Medical (ICUI) in a closely-watched patent infringement case, and ruled that RyMed's InVision-Plus with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.
Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed said the unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed's products literally infringe on an in-force ICU Medical patent.
Commention on the jury's decision, Ryan continued, " It reinforces our ability to continue providing all of RyMed's innovative technology to the market. In addition to providing a significant boost to our future business prospects, it also affirms our ongoing efforts to bring clinicians and patients the very best in IV catheter safety technology."
The jury decision was announced Wednesday, May 9th in a case heard before Judge Leonard P. Stark, in the United States District Court for the District of Delaware.
For comments and feedback: editorial@rttnews.com